Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects

Brain Research

Volumn 795, Issue 1-2, 1998, Pages 179-190

  Bymaster, Frank P ^a   Carter, Petra A ^a   Peters, Steven C ^a   Zhang, Wei ^a   Ward, John S ^a   Mitch, Charles H ^a   Calligaro, David O ^a   Whitesitt, Celia A ^a   DeLapp, Neil ^a   Shannon, Harlan E ^a   Rimvall, Karin ^b   Jeppesen, Lone ^b   Sheardown, Malcolm J ^b   Fink Jensen, Anders ^b   Sauerberg, Per ^b  

^a ELI LILLY AND COMPANY   (United States)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Acetylcholine; Alzheimer's disease; Milameline; Muscarinic agonist; Muscarinic receptor; Phosphoinositide hydrolysis; Xanomeline

Indexed keywords

2 ETHYL 8 METHYL 2,8 DIAZASPIRO[4.5]DECANE 1,3 DIONE; ACECLIDINE; CHOLINESTERASE INHIBITOR; LITHIUM; LU 25209; LY 287041; MILAMELINE; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC M2 RECEPTOR ANTAGONIST; NNC 110309; OXOTREMORINE; PD 142505; PHOSPHATIDYLINOSITIDE; PILOCARPINE; SKB 202026; THIOPILOCARPINE; UNCLASSIFIED DRUG; WAL 2014NE; XANOMELINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COGNITION; CONTROLLED STUDY; DRUG EFFECT; HYDROLYSIS; MALE; MEMORY; MOUSE; NONHUMAN; PHOSPHOINOSITIDE METABOLISM; PRIORITY JOURNAL; RADIOMETRY;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; BINDING, COMPETITIVE; BRAIN CHEMISTRY; CHOLINERGIC AGENTS; CHOLINESTERASE INHIBITORS; DIHYDROPYRIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDROLYSIS; HYPOTHERMIA; IMINES; LITHIUM; MALE; MICE; MICE, INBRED STRAINS; MUSCARINIC AGONISTS; OXIMES; PARASYMPATHOMIMETICS; PHOSPHATIDYLINOSITOLS; PHYSOSTIGMINE; PILOCARPINE; PYRIDINES; QUINUCLIDINES; RADIOLIGAND ASSAY; SALIVATION; TACRINE; TETRAZOLES; THIADIAZOLES; TREMOR;

EID: 0032496752     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(98)00267-4     Document Type: Article

References (52)

1. W.S. Adamus, J. Leonard, W. Troger, Phase I clinical trials with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer's disease, Life Sci. 56 (1995) 883-890.
2. R.T. Bartus, R.L. Dean, B. Beer, A.S. Lippa, Cholinergic hypothesis of geriatric memory dysfunction: a critical review, Science 217 (1982) 408-417.
3. 1-selective muscarinic agonist, on cognitive and behavioral symptoms in Alzheimer's disease, Arch. Neurol. 54 (1997) 465-473.
4. T.I. Bonner, N.J. Buckley, A.C. Young, M.R. Brann, Identification of a family of muscarinic acetylcholine receptor genes, Science 237 (1987) 527-532.
5. M.R. Brann, N.J. Buckley, P. Jones, T.I. Bonner, Expression of a cloned muscarinic receptor in A9 L cells, Mol. Pharmacol. 32 (1987) 450-455.
6. S.M. Bromidge, F. Brown, F. Cassidy, M.S.G. Clark, S. Dabbs, J. Hawkins, J.M. Loudon, B.S. Orlek, G.J. Riley, A novel and selective class of azabicyclic muscarinic agonists incorporating an N-methoxy imidoyl halide or nitrile functionality, Biol. Med. Chem. Lett. 2 (1992) 791-796.
7. Bromidge, S.M., Cassidy, F., Clark, M.S.G., Eggleston, D.S., Orlek, B.S., Synthesis and properties of [R-(Z)-(+)-α-(1-azabicyclo[2.2.2]oct-3-y1)-α- (methoxyimino)acetonitrile, a novel functionally selective muscarinic partial agonist, J. Chem. Soc. (1992b) 2189-2190.
8. N.J. Buckley, T.I. Bonner, M.R. Brann, Localization of a family of muscarinic receptor mRNAs in rat brain, J. Neurosci. 8 (1988) 4646-4652.
9. F.P. Bymaster, I. Heath, J.C. Hendrix, H.E. Shannon, Comparative behavioral and neurochemical activities of cholinergic antagonists in rats, J. Pharmacol. Exp. Ther. 267 (1993) 16-24.
10. F.P. Bymaster, D.T. Wong, C.H. Mitch, J.S. Ward, D.O. Calligaro, D.D. Schoepp, H.E. Shannon, M.J. Sheardown, P.H. Olesen, P.D. Suzdak, M.D.B. Swedberg, P. Sauerberg, Neurochemical effects of the M1 agonist xanomeline (LY246708/NNC11-0232), J. Pharmacol. Exp. Ther. 269 (1994) 282-289.
11. 1 agonist 3-hexylthio-TZTP(LY287041/NNC11-0309), Soc. Neurosci. Abstr. 19 (1993) 461, part 1.
12. F.P. Bymaster, C.A. Whitesitt, H.E. Shannon, N. DeLapp, J.S. Ward, D.O. Calligaro, L.A. Shipley, J.L. Buelke-Sam, N.C. Bodick, L. Farde, M.J. Sheardown, P.H. Diesen, K.T. Hansen, P.D. Suzdak, M.D.B. Swedberg, P. Sauerberg, C.H. Mitch, Xanomeline: a selective muscarinic agonist for the treatment of Alzheimer's disease, Drug Dev. Res. 40 (1997) 158-170.
13. 50) of an enzymatic reaction, Biochem. Pharmacol. 22 (1973) 3090-3108.
14. J.E. Christie, A. Shering, J. Ferguson, A.I.M. Glen, Physostigmine and arecoline: effects of intravenous infusions in Alzheimer' s Presenile Dementia, Br. J. Psychiatry 138 (1981) 46-50.
15. J.T. Coyle, D.L. Price, M.R. DeLong, Alzheimer's disease: a disorder of cortical cholinergic innervation, Science 219 (1983) 1184-1190.
16. A. De Lean, J. Munson, D. Rodbard, Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves, Am. J. Physiol. 235 (1978) E97-E102.
17. 3 muscarinic receptors in rat parotid gland couple to two second messenger systems, Am. J. Physiol. 261 (1991) C1063-C1073, Cell Physiol., 30.
18. 3 muscarinic receptors in rat parotid gland couple to two second messenger systems, Am. J. Physiol. 261 (1991) C1063-C1073, Cell Physiol., 30.
19. K. Eckols, F.P. Bymaster, C.H. Mitch, H.E. Shannon, J.S. Ward, N.W. DeLapp, The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from Chinese hamster ovary-mi cells, Life Sci. 57 (1995) 1183-1190.
20. H.A. Ensinger, H.N. Doods, A.R. Immel-Sehr, F.J. Kuhn, G. Lambrecht, K.D. Mendla, R.E. Muller, E. Mutschler, A. Sagrada, G. Walther, R. Hammer, WAL 2014 - A muscarinic agonists with preferential neuron-stimulating properties, Life Sci. 52 (1993) 473-480.
21. A. Enz, H. Boddeke, A. Sauter, M. Rudin, G. Shapiro, SDZ ENS 163 A novel pilocarpine like drug: pharmacological in vitro and in vivo profile, Life Sci. 52 (1993) 513-520.
22. A. Enz, G. Shapiro, P. Supavilai, H.G.M. Boddeke, SDZ ENS 163 is a selective M1 agonist and induces release of acetylcholine, Naunyn-Schmiedeberg's Arch. Pharmacol. 345 (1992) 282-287.
23. S.B. Freedman, E.A. Harley, L.L. Iversen, Relative affinities of drugs acting at cholinoreceptors in displacing agonist and antagonist radioligands: the NMS/OXO-M ratio as an index of efficacy at cortical muscarinic receptors, Br. J. Pharmacol. 93 (1988) 437-445.
24. S.B. Freedman, E.A. Harley, S. Patel, Direct measurement of muscarinic agents in the central nervous system of mice using ex vivo binding, Eur. J. Pharmacol. 174 (1989) 253-260.
25. 2 biochemical and functional characterization, Life Sci. 31 (1982) 2991-2998.
26. E. Hollander, R.C. Mohs, K.L. Davis, Cholinergic approaches to the treatment of Alzheimer's disease, Br. Med. Bull. 42 (1986) 97-100.
27. G.-Y. Hu, O. Hvalby, S.I. Walaas, K.A. Albert, P. Skjeflo, P. Andersen, P. Greengard, Protein kinase C injection into hippocampal pyramidal cells elicits features of long term potentiation, Nature, London 328 (1987) 426-429.
28. G. Lambrecht, R. Feifel, U. Moser, M. Wagner-Roder, L.K. Choo, J. Camu, M. Tastenoy, M. Waelbroeck, C. Strohmann, R. Tacke, J.F. Rodrigues de Miranda, J. Christophe, E. Mutschler, Pharmacology of hexahydro-difenidol and related selective muscarinic antagonists, Trends Pharmacol. Sci. 10 (1989) 60-64, suppl.
29. A.I. Levey, Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain, Life Sci. 52 (1993) 441-448.
30. M. Marchi, M. Raiteri, On the presence in the cerebral cortex of muscarinic receptor subtypes which differ in neuronal localization, function and pharmacological properties, J. Pharmacol. Exp. Ther. 235 (1985) 230-233.
31. 2 muscarinic receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation, Science 228 (1985) 1115-1117.
32. A.D. Michel, R.L. Whiting, Direct binding studies on ileal and cardiac muscarinic receptors, Br. J. Pharmacol. 92 (1987) 755-767.
33. E.K. Moltzen, H. Pedersen, K.P. Bogeso, E. Meier, K. Frederiksen, C. Sanchez, H.L. Lembol, Bioisosteres of arecoline: 1,2,3,6-tetrahydro-5-pyridyl-substituted and 3-piperidyl-substituted derivatives of tetrazoles and 1,2,3-triazoles Synthesis and muscarinic activity, J. Med. Chem. 37 (1994) 4085-4099.
34. M.M. Mouradian, E. Mohr, J.A. Williams, T.N. Chase, No response to high-dose muscarinic therapy in Alzheimer's disease, Neurology 38 (1988) 606-608.
35. R.M. Nitsch, B.E. Slack, R.J. Wurtman, J.H. Growdon, Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors, Science 258 (1992) 304-307.
36. S. Patel, S.B. Freedman, The muscarinic receptor agonist L-658,903 modulates the in vivo accumulation of inositol monophosphates in mouse brain, Eur. J. Pharmacol. 267 (1994) 329-334.
37. E.G. Peralta, A. Ashkenazi, J.W. Winslow, D.H. Smith, J. Ramachandran, D.J. Capon, Distinct primary structures, ligand-binding properties and tissue-specific expression of four human muscarinic acetylcholine receptors, EMBO J. 6 (1987) 3923-3929.
38. E.G. Peralta, A. Ashkenazi, J.W. Winslow, J. Ramachandran, D.J. Capon, Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes, Nature, London 334 (1988) 434-437.
39. 1 receptors coupled to phosphoinositide turnover, Brain Res. 693 (1995) 118-123.
40. M.H. Richards, P.L.M. van Giersbergen, Human muscarinic receptors expressed in A9L and CHO cells: activation by full and partial agonists, Br. J. Pharmacol. 114 (1995) 1241-1249.
41. B. Ringdahl, F.J. Ehlert, D.J. Jenden, Muscarinic activity and receptor binding of the enantiomers of aceclidine and its methiodide, Mol. Pharmacol. 21 (1982) 594-599.
42. 1 muscarinic acetylcholine receptor regulates τ phosphorylation in transfected PC12 cells, J. Neurochem. 66 (1996) 877-880.
43. 1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines, J. Med. Chem. 35 (1992) 2274-2283.
44. D.D. Schoepp, B.G. Johnson, Selective inhibition of excitatory amino acid-stimulated phosphoinositide hydrolysis in the rat hippocampus by activation of protein kinase C, Biochem. Pharmacol. 37 (1988) 4299-4305.
45. A.J. Sedman, H. Bockbrader, R.D. Schwarz, Preclinical and Phase I characterization of CI-979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease, Life Sci. 56 (1995) 877-882.
46. H.E. Shannon, B.D. Sawyer, K.G. Bemis, F.P. Bymaster, I. Heath, C.H. Mitch, J.S. Ward, Muscarinic M1 receptor agonist actions of muscarinic receptor agonists in rabbit vas deferens, Eur. J. Pharmacol. 232 (1993) 47-57.
47. 1 receptors, J. Pharmacol. Exp. Ther. 269 (1994) 271-281.
48. J.J. Sramek, A.J. Sedman, P.A. Reece, J. Hourani, H. Bockbrader, N.R. Cutler, Safety and tolerability of CI-979 in patients with Alzheimer's disease, Life Sci. 57 (1995) 503-510.
49. H. Tecle, J.C. Jaen, C. Augelli-Szafran, S.D. Barrett, B.W. Caprathe, D.J. Lauffer, T. Mirzadegan, W.H. Moos, D.W. Moreland, M.R. Pavia, R.D. Schwarz, A.J. Thomas, R.E. Davis, Z-(+)-1-azabicyclo[2.2.1]heptan-3-one, O-(3-aryl-2-propynyl)oximes as potential m1-subtype selective muscarinic agonists, Biol. Med. Chem. Lett. 5 (1995) 631-636.
50. M. Waelbroeck, M. Tastenoy, J. Camus, J. Christophe, Binding of selective antagonists to four muscarinic receptors (M1 to M4) in rat forebrain, Mol. Pharmacol. 38 (1990) 267-273.
51. S.Z. Wang, E.E. El-Fakahany, Application of transfected cell lines in studies of functional receptor subtype selectivity of muscarinic agonists, J. Pharmacol. Exp. Ther. 266 (1993) 237-243.
52. P.J. Whitehouse, D.L. Price, R.G. Struble, A.W. Clark, J.T. Coyle, M.R. DeLong, Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain, Science 215 (1982) 1237-1239.